{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:32:46Z","timestamp":1769106766788,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.conctc.2022.101045","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T13:38:10Z","timestamp":1670333890000},"page":"101045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The BATTLE study: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. Study protocol of a double blind, randomized, placebo-controlled trial: study protocol"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7010-7071","authenticated-orcid":false,"given":"L.C.","family":"Terpstra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Altenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bronsveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.J.","family":"Doodeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Rozemeijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.G.M.","family":"Heijerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.G.","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.conctc.2022.101045_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.7861\/clinmedicine.9-2-164","article-title":"Non-cystic fibrosis bronchiectasis","volume":"9","author":"Murray","year":"2009","journal-title":"Clin. Med."},{"issue":"5","key":"10.1016\/j.conctc.2022.101045_bib2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The bronchiectasis severity index. an international derivation and validation study","volume":"189","author":"Chalmers","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"10.1016\/j.conctc.2022.101045_bib3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/crj.13054","article-title":"Aetiology and disease severity are among the determinants of quality of life in bronchiectasis","volume":"13","author":"Terpstra","year":"2019","journal-title":"Clin. Respir. J"},{"key":"10.1016\/j.conctc.2022.101045_bib4","first-page":"6","article-title":"Inflammation: a two-edged sword--the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"Eur. J. Respir. Dis. Suppl."},{"issue":"6","key":"10.1016\/j.conctc.2022.101045_bib5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1164\/rccm.201303-0411CI","article-title":"Non\u2013cystic fibrosis bronchiectasis","volume":"188","author":"McShane","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.conctc.2022.101045_bib6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.conctc.2022.101045_bib7","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","article-title":"Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis","volume":"132","author":"Mart\u00ednez-Garc\u00eda","year":"2007","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.conctc.2022.101045_bib8","first-page":"1420","article-title":"A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis","volume":"127","author":"Scheinberg","year":"2005","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.conctc.2022.101045_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European respiratory society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.conctc.2022.101045_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.molimm.2012.09.011","article-title":"Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis","volume":"55","author":"Chalmers James","year":"2013","journal-title":"Mol. Immunol."},{"issue":"7","key":"10.1016\/j.conctc.2022.101045_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers James","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.conctc.2022.101045_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcs173","article-title":"Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis","volume":"106","author":"Mandal","year":"2013","journal-title":"QJM: Int. J. Med."},{"issue":"1","key":"10.1016\/j.conctc.2022.101045_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/34.1.149","article-title":"Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis","volume":"34","author":"Rayner","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.conctc.2022.101045_bib14","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis","volume":"7","author":"Laska","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.conctc.2022.101045_bib15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.conctc.2022.101045_bib16","article-title":"Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis","author":"Hurley","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.conctc.2022.101045_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.conctc.2022.101045_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO;2-J","article-title":"Placebo\u2010controlled, double\u2010blind, randomized study of aerosolized tobramycin for early treatment of pseudomonas aeruginosa colonization in cystic fibrosis","volume":"25","author":"Wiesemann","year":"1998","journal-title":"Pediatr. Pulmonol."},{"issue":"12","key":"10.1016\/j.conctc.2022.101045_bib19","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S2213-2600(16)30320-4","article-title":"Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study","volume":"4","author":"McDonnell","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"2 Pt 1","key":"10.1016\/j.conctc.2022.101045_bib20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.conctc.2022.101045_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1345\/aph.1E099","article-title":"Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with pseudomonas aeruginosa","volume":"39","author":"Drobnic","year":"2005","journal-title":"Ann. Pharmacother."},{"issue":"7","key":"10.1016\/j.conctc.2022.101045_bib22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0954-6111(99)90090-2","article-title":"Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by pseudomonas aeruginosa","volume":"93","author":"Orriols","year":"1999","journal-title":"Respir. Med."},{"issue":"12","key":"10.1016\/j.conctc.2022.101045_bib23","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non\u2013cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.conctc.2022.101045_bib24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/biomet\/78.2.446","article-title":"Sample size for Poisson regression","volume":"78","author":"Signorini","year":"1991","journal-title":"Biometrika"},{"issue":"1","key":"10.1016\/j.conctc.2022.101045_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2014-205918","article-title":"Quality of life questionnaire-bronchiectasis: final psychometric analyses and determination of minimal important difference scores","volume":"70","author":"Quittner","year":"2015","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.conctc.2022.101045_bib26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/crj.12198","article-title":"Validation of a visual analogue score (LRTI-VAS) in non-CF bronchiectasis","volume":"10","author":"Altenburg Josje","year":"2016","journal-title":"Clinical Respiratory Journal, The."},{"issue":"1","key":"10.1016\/j.conctc.2022.101045_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1183\/09031936.00160508","article-title":"Validation of the leicester cough questionnaire in non-cystic fibrosis bronchiectasis","volume":"34","author":"Murray","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.conctc.2022.101045_bib28","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit Timothy","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.conctc.2022.101045_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02052-2017","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"De Soyza","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.conctc.2022.101045_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.conctc.2022.101045_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. cystic fibrosis inhaled tobramycin study group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.conctc.2022.101045_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0924-8579(02)00030-4","article-title":"Extended interval aminoglycoside dosing: from concept to clinic","volume":"19","author":"Maglio","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.conctc.2022.101045_bib33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: Critical interactions of'bug and drug","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"issue":"3","key":"10.1016\/j.conctc.2022.101045_bib34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1586\/14787210.4.3.479","article-title":"Influence of pharmacokinetics\/pharmacodynamics of antibacterials in their dosing regimen selection","volume":"4","author":"Scaglione","year":"2006","journal-title":"Expert Rev. Anti-infect. Ther."},{"issue":"5","key":"10.1016\/j.conctc.2022.101045_bib35","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1378\/chest.112.5.1208","article-title":"Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis","volume":"112","author":"Bates","year":"1997","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.conctc.2022.101045_bib36","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/clinids\/24.5.810","article-title":"Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review","volume":"24","author":"Hatala","year":"1997","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.conctc.2022.101045_bib37","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1542\/peds.114.1.e111","article-title":"Extended-interval aminoglycoside administration for children: a meta-analysis","volume":"114","author":"Contopoulos-Ioannidis","year":"2004","journal-title":"Pediatrics"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865422001624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865422001624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:07:36Z","timestamp":1762520856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865422001624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":37,"alternative-id":["S2451865422001624"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2022.101045","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The BATTLE study: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. Study protocol of a double blind, randomized, placebo-controlled trial: study protocol","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2022.101045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101045"}}